Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
American Journal of Hematology · 2026-12 · 101 (12) · 2990-3000
DOI: 10.1002/ajh.70500 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 17.09.2026. Verfasst von Sudhesh Kumar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Patients with newly‐diagnosed acute myeloid leukemia (ND‐AML) derive variable survival benefit from venetoclax (Ven) plus hypomethylating agent (HMA) therapy, and the optimal Ven duration across genetic risk groups remains undefined. Among 540 ND‐AML patients receiving Ven‐HMA at Mayo Clinic, outcomes were compared across Ven 7‐ ( n = 33), 14‐ ( n = 117), 21‐ ( n = 96), and 28‐day ( n = 294) schedules during Cycle 1 and stratified by ELN 2024 and Mayo genetic risk groups. At a median follow‐up of 37.7 months, allogeneic stem cell transplant (ASCT) rates were similar across Ven duration groups (15%, 18%, 18%, and 20% for 7‐, 14‐, 21‐, and 28‐day; p = 0.86). Median transplant‐censored survival was comparable across Ven durations (13.3, 11.9, 16.8, and 13.2 months for 7, 14, 21, 28 days, respectively; p = 0.65), with outcomes driven by ELN risk (6.3, 11.5, 18.3 months for high, intermediate, low; p < 0.01) and Mayo genetic risk (6.9, 17.8 months, not reached; p < 0.01). Survival was comparable across Ven durations within ELN intermediate/low‐risk and all Mayo risk groups. Among ELN high‐risk patients, 14‐day Ven was associated with inferior transplant‐censored survival compared to 21‐ and 28‐day schedules ( p < 0.01). Notably, 30‐ and 60‐day mortality were higher with shorter Ven schedules (7‐day: 9%/18%; 14‐day: 7%/15%) versus 28‐day (2%/6%), which likely reflects treatment selection bias. In ND‐AML, no significant difference in transplant‐censored survival was observed across the 7‐, 14‐, 21‐, and 28‐day Ven schedules; prognosis was determined primarily by Mayo and ELN 2024 genetic risk rather than by Ven duration. Prospective trials are needed to establish risk‐adapted Ven dosing strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA.
ORCID-Profile: Sudhesh Kumar, Momna Warraich, Mahnoor Fatima, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Abhishek A Mangaonkar, Antoine N Saliba, Mark R Litzow, William Hogan, Mithun Shah, Mrinal M Patnaik, Animesh Pardanani, Talha Badar, James Foran, Ayalew Tefferi, Naseema Gangat
Zitieren
APA
Kumar, S., Warraich, M., Fatima, M., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A. A., Saliba, A. N., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Badar, T., Foran, J., Palmer, J., Yi, C. A., Tefferi, A., & Gangat, N. (2026). Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients. American Journal of Hematology, 101(12), 2990-3000. https://doi.org/10.1002/ajh.70500
Vancouver
Kumar S, Warraich M, Fatima M, McCullough K, Al-Kali A, Alkhateeb HB, et al. Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients. American Journal of Hematology. 2026;101(12):2990-3000. doi:10.1002/ajh.70500
BibTeX
@article{Kumar2026,
author = {Kumar, Sudhesh and Warraich, Momna and Fatima, Mahnoor and McCullough, Kristen and Al-Kali, Aref and Alkhateeb, Hassan B and Begna, Kebede H and Mangaonkar, Abhishek A and Saliba, Antoine N and Litzow, Mark R and Hogan, William and Shah, Mithun and Patnaik, Mrinal M and Pardanani, Animesh and Badar, Talha and Foran, James and Palmer, Jeanne and Yi, Cecilia Arana and Tefferi, Ayalew and Gangat, Naseema},
title = {Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {12},
pages = {2990--3000},
doi = {10.1002/ajh.70500}
}
EUVIMED